 **Defensible?** Not defensible.  

**Argument:**  
The Executive Summary’s three claims collapse under contradictions exposed by Statements 2–5, 7–8, and 10.  

1. **Claim of completeness** (Executive Summary first bullet) is refuted by Statement 5: Table 2 lists only **CF‑A** for all tests, yet Statement 2 explicitly confirms **CF‑B** was used in trials. This omission violates HELIO‑STD‑X719’s requirement (Statement 10) to document all configurations, rendering the memo incomplete.  

2. **Claim of standards compliance** (second bullet) is undermined by Statement 3: **CF‑B** was used in testing but lacks certification (Statement 3), and its data is not traceable per HELIO‑STD‑X719 (Statement 10). The memo’s assertion that “all test data meet requirements” ignores this violation, as uncertified configurations used in qualification testing cannot legitimately satisfy standards mandating traceability.  

3. **Claim of “no unmitigated risks”** (third bullet) is falsified by Statement 8: CF‑B Test AB‑17’s transient bus resets were identified but excluded from Section 5 (Statement 7), which only details CF‑A anomalies. HELIO‑STD‑X719 mandates disclosing anomalies in non-certified configurations that could “mask” certified behavior (Statement 10). By omitting CF‑B’s unresolved issues, the memo fails to address these risks, leaving them unmitigated.  

The structural collapse is inevitable: the omission of **CF‑B** in Table 2 and Section 5, coupled with its unreported anomalies, directly contradicts all three Executive Summary claims. Compliance with HELIO‑STD‑X719 and assertions of completeness/risk-free status cannot hold under these omissions.